PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
10.2147/ott.s309661
Saved in:
Main Authors: | Sachdeva, Manavi, Ngoi, Natalie YL, Lim, Diana, Poon, Michelle LM, Thian, Yee Liang, Lim, Yi Wan, Lim, Siew Eng, Tong, Pearl, Lum, Jeffrey HY, Ng, Joseph, Ilancheran, Arunachalam, Domingo, Efren J, Low, Jeffrey JH, Tan, David SP |
---|---|
Other Authors: | DIAGNOSTIC RADIOLOGY |
Format: | Article |
Published: |
Informa UK Limited
2021
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/192326 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
by: Ngoi, NYL, et al.
Published: (2021) -
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
by: Lee, Yong Jae, et al.
Published: (2021) -
Cutaneous T-cell lymphoma of the vulva
by: Dashraath, Pradip, et al.
Published: (2021) -
Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
by: Kim, YN, et al.
Published: (2023) -
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
by: Ngoi, Natalie YL, et al.
Published: (2020)